Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 0.86 |
| ▸ | ALB | P02768 | 1/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757554 | 1.00 | TSPO (0.86) | TSPOALBOPRK1 | |
| SCHEMBL16569003 | 0.93 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL12405739 | 0.91 | TSPO (0.78) | TSPOALBOPRK1 | |
| SCHEMBL18068951 | 0.90 | TSPO (0.83) | TSPOALBOPRK1 | |
| SCHEMBL2757580 | 0.89 | TSPO (0.69) | TSPOALBOPRK1 | |
| SCHEMBL2757551 | 0.87 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL2757548 | 0.87 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL29377466 | 0.87 | TSPO (1.00) | TSPOALBOPRK1 | |
| SCHEMBL2757561 | 0.86 | TSPO (0.65) | TSPOALBOPRK1 | |
| SCHEMBL13161736 | 0.86 | TSPO (0.65) | TSPOALBOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250195602-A1 | Compositions and Methods for Treating Neuropathy | CREATIVE BIO-PEPTIDES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12325744-B2 | Methods for reducing post-operative cognitive dysfunction (POCD) | THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH (GB) | 2025-06-10 | — | — | US | disclosed |
| WO-2025038692-A2 | DEEP REGRESSION ESTIMATION OF ARTERIAL INPUT FUNCTION FOR DYNAMIC PET | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20240252583-A1 | Compositions and Methods for Treating Persistent Postsurgical Pain | CREATIVE BIO-PEPTIDES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | HEALTH, SANFORD | 2024-06-20 | — | — | US | disclosed |
| EP-4352075-A1 | COMPOSITIONS AND METHODS FOR TREATING PERSISTENT POSTSURGICAL PAIN | Creative Bio-Peptides Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4340860-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | Creative Bio-Peptides Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4313016-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Sanford Health (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | disclosed |
| US-11712487-B2 | Composite embolization beads | RAIKA MEDICAL IMAGING INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-113387896-B | 4- (2-chloro aryl) quinazoline-2-amide derivative and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2023-03-24 | — | — | CN | disclosed |
| WO-2022261321-A1 | COMPOSITIONS AND METHODS FOR TREATING PERSISTENT POSTSURGICAL PAIN | CREATIVE BIO-PEPTIDES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-110229093-B | Carbazole compounds for in vivo imaging | 通用电气健康护理有限公司 | 2022-12-13 | — | — | CN | disclosed |
| WO-2022246233-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CREATIVE BIO-PEPTIDES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022212273-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | SANFORD HEALTH (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212271-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | SANFORD HEALTH (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212268-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | SANFORD HEALTH (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220112281-A1 | METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | TSPO 264/4885ALB 142/4885OPRK1 2863/4885 |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | TSPO 1844/4885ALB 2713/4885OPRK1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.